Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Leads Investment in U.S. Oncology Startup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2019 | 09:26am EDT

By Kim Richters

Germany's Bayer AG (BAYN.XE) said Wednesday that it has led a financing round in a U.S. startup researching potential cancer treatments.

The German conglomerate, which is battling legal cases in the U.S. tying its Roundup weedkiller to cancer, said it had invested $11 million in startup Pyxis Oncology via its investment arm Leaps by Bayer. Investors Agent Capital, Ipsen and Longwood Fund also contributed another $11 million, according to Bayer.

The newly founded Pyxis aims to develop antibody-based immunotherapies for cancer patients.

Write to Kim Richters at kim.richters@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
08/16Materials up Amid Hopes for Stimulus -- Materials Roundup
DJ
08/13Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructur..
AQ
08/12CORRECTION : Weed Killer-Label story
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/09Materials Down After Trump Comments on Trade Negotiations -- Materials Roundu..
DJ
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 4th Upda..
DJ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09BAYER MEDIATOR : $8 Billion Roundup Settlement Report 'Pure Fiction' -- 3rd Upda..
DJ
08/09NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/09NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (EUR)
Sales 2019 46 199 M
EBIT 2019 8 364 M
Net income 2019 3 352 M
Debt 2019 37 554 M
Yield 2019 4,42%
P/E ratio 2019 20,2x
P/E ratio 2020 13,7x
EV / Sales2019 2,11x
EV / Sales2020 2,00x
Capitalization 60 140 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,86  €
Last Close Price 64,49  €
Spread / Highest target 90,7%
Spread / Average Target 20,7%
Spread / Lowest Target -39,9%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG6.69%65 567
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.10.66%235 575
ROCHE HOLDING12.11%235 575
MERCK AND COMPANY9.23%213 689
NOVARTIS17.91%202 958